Related Experiment Video
Updated: Apr 23, 2026
06:10
Encapsulated Cell Technology for the Delivery of Biologics to the Mouse Eye
Published on: March 30, 2020
7.4K
Is systemic infliximab therapy effective for retinal cavernous hemangioma?
Sulaiman M Alsulaiman1, Marwan A Abouammoh, Saad A Al-Dahmash
1Department of Ophthalmology, College of Medicine, King Saud University, Riyadh, Kingdom of Saudi Arabia. E-mail. dr.abouammoh@gmail.com.
Saudi Medical Journal
|September 18, 2014
Summary
A 10-month-old infant with retinal cavernous hemangioma showed no improvement after infliximab treatment. This suggests infliximab may not be effective for this rare vascular tumor in infants.
Area of Science:
- Ophthalmology
- Vascular Biology
- Pediatric Medicine
Background:
- Retinal cavernous hemangioma is a rare, benign vascular tumor.
- Macular involvement can lead to significant visual impairment.
- Treatment options for pediatric retinal cavernous hemangioma are limited.
Observation:
- A 10-month-old infant presented with strabismus and vitreous hemorrhage.
- Funduscopic examination revealed a macular retinal cavernous hemangioma with characteristic grape-like clusters.
- The infant had an outward deviation of the right eye.
Findings:
- Intravenous infliximab was administered over 3 months (4 cycles).
- No significant change in the size of the retinal cavernous hemangioma was observed post-treatment.
- The vitreous hemorrhage showed clearing, but the hemangioma itself remained unchanged.
Implications:
- Infliximab may not be an effective treatment for retinal cavernous hemangioma in infants.
- Further research is needed to explore alternative therapeutic strategies.
- This case highlights the challenges in managing pediatric retinal vascular tumors.
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
863
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
863
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
739
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
739
01:27Open Angle Glaucoma: Treatment
1.0K
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.0K
01:28Angle Closure Glaucoma: Treatment
1.6K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.6K